Jill Escher
Autism researcher and NCSA president
Jill Escher is a US autism researcher and president of the National Council on Severe Autism whose personal story carries direct relevance for British listeners. Her discovery that her mother received weekly synthetic hormone injections during a 1965 pregnancy led her to investigate whether prenatal steroid exposure underpins the modern surge in both autism and gender dysphoria.
Jill Escher is president of the National Council on Severe Autism (NCSA), a US advocacy organisation focused on individuals with profound autism. Her research into the environmental origins of autism grew from a personal discovery: her mother received weekly synthetic hormone injections during a 1965 pregnancy—a practice once considered routine protection against miscarriage on both sides of the Atlantic, including on the NHS.
In the Beyond Gender episode Poisoned in the Womb: When Medicine's Mistakes Echo Through Generations (episode 19, June 2025), Escher joined hosts Stella O'Malley, Mia Hughes and Dr Bret Alderman to argue that prenatal steroid exposure may be a significant driver of the modern surge in both autism and gender dysphoria. The British dimension is direct: drugs such as diethylstilbestrol (DES) and synthetic progestogens were prescribed on the NHS during the same era, meaning a cohort of British people may carry comparable prenatal exposures. The Cass Review, published in 2024, independently flagged the high overlap between autism and gender dysphoria presentations—precisely the territory Escher had begun mapping from an environmental and multigenerational perspective.
Her analysis raises questions that Britain's post-Tavistock gender services have yet to fully engage with: if prenatal hormonal disruption shapes neurological development and later gender-identity presentations, should clinical assessment look further back than adolescence? Escher's work adds a biological dimension to a debate that in the UK has largely been framed in psychological and safeguarding terms.
For British listeners, her testimony is a reminder that pharmaceutical decisions made for one generation can reverberate invisibly through the next—a lesson the NHS has confronted before, and may need to confront again.
